A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.

Trial Details

NCT ID

NCT07309276

Phase

PHASE2

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

JS212 for Injection
JS207 for Injection
Toripalimab
JS213 for Injection

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

The age between 18 and 75 years old, and any gender.
Local advanced, metastatic or recurrent NSCLC.
According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →